Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Panbela Therapeutics's Enterprise Value is $6.31 Mil.
Panbela Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-15.57 Mil. Therefore, Panbela Therapeutics's EV-to-FCF for today is -0.40.
The historical rank and industry rank for Panbela Therapeutics's EV-to-FCF or its related term are showing as below:
PBLA'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.4 Med: 0 Max: 0
Current: -0.4
PBLA's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 15.15
vs PBLA: -0.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panbela Therapeutics's PE Ratio (TTM) for today is calculated as:
Panbela Therapeutics's share price for today is $0.0111.
Panbela Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.717.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Panbela Therapeutics EV-to-FCF Related Terms
Panbela Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Panbela Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Panbela Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panbela Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Panbela Therapeutics's EV-to-FCF falls into.
Panbela Therapeutics's current Enterprise Value is $6.31 Mil.
Panbela Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panbela Therapeutics (PBLA) has a EV-to-FCF of -0.40 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Panbela Therapeutics and its competitors.
Is Panbela Therapeutics' EV-to-FCF too high?
Panbela Therapeutics' current EV-to-FCF is -0.40.
How does Panbela Therapeutics' EV-to-FCF compare to VINC and OMGAQ?
Panbela Therapeutics' EV-to-FCF of -0.40 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 15.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.15, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Panbela Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panbela Therapeutics's current EV-to-FCF is -0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panbela Therapeutics stock overvalued right now?
Panbela Therapeutics (PBLA) has a current EV-to-FCF of -0.40. The current EV-to-FCF is -0.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Panbela Therapeutics (PBLA), the current EV-to-FCF is -0.40 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLA has been successfully added to your 
